Advanced search
Publication Cover
Emerging Therapeutic Targets Volume 3, 1999 - Issue 2
Journal homepage
16
Views
0
CrossRef citations to date
0
Altmetric
Review

Emerging therapeutic targets in staphylococcal infections

L Vincent Collins Department of Rheumatology, University of Göteborg, Guldhedsgatan 10, S-413 46 Göteborg, Sweden. Tel: +46 31 342 6475; Fax: +46 31 823 925; [email protected]
&
Andrej Tarkowski Department of Rheumatology, University of Göteborg, Guldhedsgatan 10, S-413 46 Göteborg, Sweden. Tel: +46 31 342 6475; Fax: +46 31 823 925; [email protected]
Pages 241-250 | Published online: 25 Feb 2005

Bibliography

  • LOWY FD: Staphylococcus aureus infections. NewEngl.J. Med. (1998) 339:520–532.
  • ••This article discusses the progress which has been made incombating S. aureus infections.
  • CENTERS FOR DISEASE CONTROL: National nosocomial infection surveillance system report: data summary from October 1986-April 1996. US Dept. Health Social Services (1996).
  • DE KIMPE SJ, KENGATHARAN M, THIEMERMANN C, VANE JR: The cell wall components peptidoglycan and lipoteichoic acid from Staphylococcus aureus act in synergy to cause shock and multiple organ failure. Proc. Natl. Acad. Sci. USA (1995) 92:10359–10363.
  • MATTSSON E, VERHAGE L, ROLLOF J et al. Peptidoglycan and teichoic acid from Staphylococcus epidermidis stimulate human monocytes to release tumour necrosis factor-alpha, interleukin-1 beta and interleukin-6. FEMS Immunol. Med. Microbic)]. (1993) 7:281–287.
  • FOSTER TJ, HOOK M: Surface protein adhesins ofStaphylococcus aureus. Trends Microbiol. (1998) 6:484–488.
  • •Summary of currently known adhesins of S. aureus.
  • PROJAN SJ, NOVICK RP: The molecular basis of pathogenicity. In: The Staphylococci in Human Disease. Crossley KB, Archer GL (Eds.), Churchill Livingstone, Inc., Philadelphia, USA (1997):55–81.
  • ••Comprehensive overview of staphylococcal virulencefactors.
  • TARKOWSKI A, WAGNER H: Arthritis and sepsis caused by Staphylococcus aureus: can the tissue injury be reduced by modulating the host's immune system? Mai Med. Today (1998) 4:15–18.
  • RECSEI P, KREISWIRTH B, O'REILLY M et al. Regulation of exoprotein gene expression in Staphylococcus aureus by agr. Mol. Gen. Genet. (1986) 202:58–61.
  • CHEUNG AL, KOOMEY JM, BUTLER CA, PROJAN SJ, FISCHETTI VA: Regulation of exoprotein expression in Staphylococcus aureus by a locus (sar) distinct from agr. Proc. Natl. Acad. ScL USA (1992) 89:6462–6466.
  • MANNA AC, BAYER MG, CHEUNG AL: Transcriptional analysis of different promoters in the sar locus in Staphylococcus aureus. J. Bacteriol. (1998) 180:3828–3836.
  • CHIEN Y, CHEUNG AL: Molecular interactions between two global regulators, sar and agr, in Staphylococcus aureus. J. Biol. Chem. (1998) 273:2645–2652.
  • NOVICK RP, ROSS HF, PROJAN SJ et al. Synthesis of staphylococcal virulence factors is controlled by a regulatory RNA molecule. EMBOJ (1993) 12:3967–3975.
  • BALABAN N et al: Auto-inducer of virulence as a target for vaccine and therapy against Staphylococcus aureus. Science (1998) 280:438–440.
  • •Demonstration of antistaphylococcal peptide therapy in mice.
  • JI G, BEAVIS RC, NOVICK RP: Cell density control of staphylococcal virulence mediated by an octapeptide pheromone. Proc. Natl. Acad. Sci. USA (1995) 92:12055–12059.
  • •Evidence for auto-induction of virulence by S. aureus.
  • MAYVILLE P, JI G, BEAVIS R et al. Structure-activity analysis of synthetic auto-inducing thiolactone peptides from Staphylococcus aureus responsible for virulence. Proc. Natl. Acad. ScL USA (1999) 96:1218–1223.
  • SAKINIENE E, BREMELL T, TARKOWSKI A: Addition of corticosteroids to antibiotic treatment ameliorates the course of experimental Staphylococcus aureus arthritis. Arthritis Rheum. (1996) 39:1596–1605.
  • VERBA V, SAKINIENE E, TARKOWSKI A: Beneficial effect of glucocorticoids on the course of haematogenously acquired Staphylococcus aureus nephritis. Scand. J. Immunol. (1997) 45:282–386.
  • PANLILIO AL, CULVER DH, GAYNES RP et aL: Methicillin-resistant Staphylococcus aureus in US hospitals, 1975-1991. Infect. Contr. Hosp. Epidemiol. (1992) 13:582–586.
  • Reduced susceptibility of Staphylococcus aureus to vancomycin-Japan, 1996. MMWR Morb. Mortal. Wkly. Rep. (1997) 46:624-626.
  • Staphylococcus aureus with reduced susceptibility to vancomycin-United States, 1997. MMWR Morb. Mortal. Wkly. Rep. (1997) 46:813–815.
  • ROTUN SS, MCMATH V, SCHOONMAKER et al. Staphylo-coccus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia. Emerg. Infect. Dis. (1999) 5:147–149.
  • •This paper covers the third and latest case reported in the US of vancomycin-resistant S. aureus.
  • DOWZICKY M, NADLER HL, FEGER C et al. Evaluation ofin vitro activity of quinupristin/dalfopristin and comparator antimicrobial agents against worldwideclinical trial and other laboratory isolates. Am. J. Med. (1998) 104:34S–42S.
  • BOUANCHAUD DH: In-vitro and in-vivo antibacterialactivity of quinupristin/dalfopristin. J. Antimicrob. Chemother. (1997) 39(Suppl. A) :15–21.
  • •This paper shows how this new drug is effective against drug-resistant staphylococci.
  • JONES RN, LOW DE, PFALLER MA: Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant Gram-positive bacteria: the role of streptogramins and other newer compounds. Diagn. Microbic]. Infect. Dis. (1999) 33:101–112.
  • LEE JC: The prospects for developing a vaccine against Staphylococcus aureus. Trends Microbiol. (1996) 4:162–166.
  • ••Review of current staphylococcal vaccine candidates.
  • LEE JC, PARK JS, SHEPHERD SE, CAREY V, FATTOM A:Protective efficacy of antibodies to the Staphylococcus aureus Type 5 capsular polysaccharide in a modified model of endocarditis in rats. Infect. Immun. (1997) 65:4146–4151.
  • WOODY MA, KRAKAUER T, ULRICH RG, STILES BG: Differential immune responses to staphylococcal enterotoxin B mutations in a hydrophobic loop dominating the interface with major histocompati-bility complex class II receptors. J. Infect. Dis. (1998) 177:1013–1022.
  • SCHENNINGS T, HEIMDAHL A, COSTER K, FLOCK JI: Immunization with fibronectin binding protein from Staphylococcus aureus protects against experimental endocarditis in rats. Microb. Pathog. (1993) 15:227–236.
  • MCDEVITT D, FRANCOIS P, VAUDAUX P, FOSTER TJ: Molecular characterization of the clumping factor (fibrinogen receptor) of Staphylococcus aureus. MoL Microbiol. (1994) 11:237–248.
  • PATTI JM, BREMELL T, KRAJEWSKA-PIETRASIK D et al.The Staphylococcus aureus collagen adhesin is a virulence determinant in experimental septic arthritis. Infect. Immun. (1994) 62:152–161.
  • NILSSON IM, PATTI JM, BREMELL T, HOOK M, TARKOWSKI A: Vaccination with a recombinant fragment of collagen adhesin provides protection against Staphylococcus aureus-mediated septic death.Clin. Invest. (1998) 101:2640–2649.
  • ZHAO YX, LJUNGDAHL A, OLSSON T, TARKOWSKI A: In situ hybridization analysis of synovial and systemic cytokine messenger RNA expression in superantigen-mediated Staphylococcus aureus arthritis. Arthritis Rheum. (1996) 39:959–967.
  • ZHAO YX, TARKOWSKI A: Impact of interferon-gamma receptor deficiency on experimental Staphylococcus aureus septicemia and arthritis. J. Immunol. (1995) 155:5736–5742.
  • ZHAO YX, NILSSON IM, TARKOWSKI A: The dual role ofinterferon-gamma in experimental Staphylococcus aureus septicaemia versus arthritis. Immunology (1998) 93:80–85.
  • HULTGREN O, KOPF M, TARKOWSKI A: Staphylococcusaureus-induced septic arthritis and septic death is decreased in IL-4-deficient mice: role of IL-4 as promoter for bacterial growth. J. Immunol (1998) 160:5082–5087.
  • HULTGREN O, EUGSTER HP, SEDGWICK JD, KORNER H, TARKOWSKI A: TNE/Iymphotoxin-alpha double-mutant mice resist septic arthritis but display increased mortality in response to Staphylococcus aureus. J. Immunol (1998) 161:5937–5942.
  • BREMELL T, LANGE S, SVENSSON L et al. Outbreak ofspontaneous staphylococcal arthritis and osteitis in mice. Arthritis Rheum. (1990) 33:1739–1744.
  • BREMELL T, ABDELNOUR A, TARKOWSKI A: Histopa-thological and serological progression of experi-mental Staphylococcus aureus arthritis. Infect. Immun. (1992) 60:2976–2985.
  • BREMELL T, LANGE S, YACOUB A, RYDEN C, TARKOWSKIA: Experimental Staphylococcus aureus arthritis in mice. Infect. Immun. (1991) 59:2615–2623.
  • ABDELNOUR A, ARVIDSON S, BREMELL T, RYDEN C, TARKOWSKI A: The accessory gene regulator (agr) controls Staphylococcus aureus virulence in a murine arthritis model. Infect. Immun. (1993) 61:3879–3885.
  • NILSSON IM, BREMELL T, RYDEN C, CHEUNG AL, TARKOWSKI A: Role of the staphylococcal accessory gene regulator (sar) in septic arthritis. Infect. Immun. (1996) 64:4438–4443.
  • NILSSON IM, LEE JC, BREMELL T, RYDEN C, TARKOWSKI A: The role of staphylococcal polysaccharide microcapsule expression in septicemia and septic arthritis. Infect. Immun. (1997) 65:4216–4221.
  • VERDRENGH M, TARKOWSKI A: Role of neutrophils in experimental septicemia and septic arthritis induced by Staphylococcus aureus. Infect. Immun. (1997) 65:2517–2521.
  • ABDELNOUR A, BREMELL T, HOLMDAHL R, TARKOWSKIA Clonal expansion of T lymphocytes causes arthritis and mortality in mice infected with toxic shocksyndrome toxin-l-producing staphylococci. Eur. J. Immunol. (1994) 24:1161–1166.
  • ABDELNOUR A, ZHAO YX, HOLMDAHL R, TARKOWSKI A: Major histocompatibility complex class II region confers susceptibility to Staphylococcus aureus arthritis. Scand. j Immunol (1997) 45:301–307.
  • COULTER SN, SCH WAN WR, NG EY et al.: Staphylococcus aureus genetic loci impacting growth and survival in multiple infection environments. Mol. Microbic)]. (1998) 30:393–404.
  • MET JM, NOURBAKHSH F, FORD CW, HOLDEN DW: Identification of Staphylococcus aureus virulence genes in a murine model of bacteraemia using signature-tagged mutagenesis. Mol Microbiol (1997) 26:399–407.
  • SONG XY, GU M, JIN WW, KLINMAN DM, WAHL SM: Plasmid DNA encoding transforming growth factor-bet al suppresses chronic disease in a streptococcal cell wall-induced arthritis model. J. Clin. Invest. (1998) 101:2615–2621.

Websites

  • Http://www.cdc.gov/ncidod/hip/staphv.htm Hospital Infections Program, National Center for Infectious Diseases, Centers for Disease Control and Prevention. (1998).
  • Http://www.genome.ou.edu/staph.html The University of Oklahoma. Staphylococcus aureus Genome Sequencing Project.
  • Http://www.tigr.org/tdb/mdb/mdb.html The Institute for Genome Research. TIGR Microbial Databases. (1999).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.